Access the data that supports our tests and technology.
Critical titers reached in 70% (FA-positive) and 69% (FA-negative) of pregnancies
Titers after cfDNA shows fetal antigen negative can be misleading and result in negative downstream impacts
Retrospective review of 100,106 consecutive general-risk pregnant patients
95% of high-risk pregnancies had at least one eligible variant for CFTR-modulator-therapy
Performance of UNITY in the CFTR gene: 100% sensitivity, >99% NPV, ~60% PPV
401 clinical outcomes
5 RHD(Ѱ) + 5 RHD-CE-D hybrid genes detected
100% concordance to neonatal outcomes
Over 465 neonatal outcomes collected
99.7% sensitivity & 99.9% specificity
Results applicable to a general obstetric population: 80% of patients in the study were <35 years of age
Global collaboration with Johnson & Johnson
99.8% NPV and 96% assay sensitivity
100% of 9-out-of-10 risk were confirmed to be affected via neonatal outcomes
Analytical sensitivity and specificity of >99.9%
93.3% clinical sensitivity in 191 cases with outcome data compared to ~35% of traditional carrier screening
99.4% NPV in a high-risk population
Accurately identified all affected pregnancies as high risk at a greater than 9 in 10 risk
All unaffected pregnancies were accurately identified as low/decreased risk
The cost to detect one affected pregnancy by carrier screening with reflex to single-gene NIPT was 62% lower than traditional carrier screening
Analytical validity of single-gene NIPT with an estimated sensitivity of >98% and specificity of >99%
